Schedule 13G ownership disclosure

CYTOSORBENTS CORP

Common Stock, par value $0.001 per share · CUSIP: 23283X206

Event date: 2024-06-26

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Avenue Venture Opportunities Fund, L.P.

    Shares: 1,126,582.00 · Class: 1.7%

  • Avenue Venture Opportunities Fund II, L.P.

    Shares: 2,628,691.00 · Class: 4.0%

  • Avenue Capital Management II, L.P.

    Shares: 3,755,273.00 · Class: 5.7%

  • Avenue Venture Opportunities Partners, LLC

    Shares: 1,126,582.00 · Class: 1.7%

  • Avenue Venture Opportunities Partners II, LLC

    Shares: 2,628,691.00 · Class: 4.0%

  • GL Venture Opportunities Partners, LLC

    Shares: 1,126,582.00 · Class: 1.7%

  • GL Venture Opportunities Partners II, LLC

    Shares: 2,628,691.00 · Class: 4.0%

  • Marc Lasry

    Shares: 3,755,273.00 · Class: 5.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001829126-25-004013
Form type
SCHEDULE 13G
Filer
Avenue Venture Opportunities Fund, L.P.
CIK
CIK 1792691
Filed
May 28, 2025
Reporting period
Jun 26, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub